Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis. 2019;78:1463–71.
2. Holdsworth EA, Donaghy B, Fox KM, et al. Biologic and targeted synthetic DMARD utilization in the United States: Adelphi real world disease specific programme for rheumatoid arthritis. Rheumatol Ther. 2021;8(4):1637–49.
3. Hsieh P, Wu O, Geue C, et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020;79(6):771–7.
4. Benjamin O, Goyal A., Lappin SL. 2022. Disease modifying anti-rheumatic drugs (DMARD). StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 4, 2022. Disease Modifying Anti-Rheumatic Drugs (DMARD) - StatPearls - NCBI Bookshelf (nih.gov)
5. Fraenkel L, Bathon JM, England BR, et al. 2021American College of Rheumatology guidelines for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–39.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献